Who
David J. Borges
VP, Finance & CAO
Company insider
Files Form 4 as: VP, Finance & CAO, Omeros.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $2.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Jun 2025
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 23 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $156K10,000 at $15.58 | filing |
| 23 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $210K10,000 at $20.95 | filing |
| 23 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 23 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $156K10,000 at $15.58 | filing |
| 23 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $210K10,000 at $20.95 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $20K5,000 at $3.93 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $15K5,000 at $2.94 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $210K10,000 at $20.95 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $20K5,000 at $3.93 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $15K5,000 at $2.94 | filing |
| 22 Sep 2026filed 24 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $210K10,000 at $20.95 | filing |
| 24 Aug 2026filed 25 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —906 at $0.00 | filing |
| 24 Aug 2026filed 25 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $2,664906 at $2.94 | filing |
| 24 Aug 2026filed 25 Aug 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $17K906 at $19.10 | filing |
| 24 Aug 2026filed 25 Aug 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —906 at $0.00 | filing |
News
Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab OpinionOMER · rttnews.com · 16 Oct 2026
0 headlines in the last 90 days name David J. Borges; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.